‘What is happening, even if focused ultrasound is approved by the Food and Drug Administration as a treatment for uterine fibroids and has shown significant advantages over competing therapies,’ he notes. ‘These benefits include being an outpatient procedure with quick recovery and preservation of fertility potential for the future.’Mankin research, funded by the National Science Foundation, was published in the journal Molecular Cell.
According to Klees, the design of studies that address the reality of the market requires an understanding of what is valued by different groups. ‘We know that doctors are looking for advanced treatment modalities to solve medical problems, patients who want to avoid surgery and long recovery times complex, and taxpayers expect results and greater efficiency in medical treatment,’ explains .
Klees said that healthcare costs are skyrocketing asked insurers to ask for best results throughout the greater value, better results, improved patient satisfaction and effective cure. In fact, many experts believe that more evidence is required to qualify for reimbursement to receive regulatory approval for new medical devices.
Unconvinced by the body of evidence, many American health insurers need randomized controlled trials and long-term results before returning to their position in the MRI-guided ultrasound targeted treatment.
Although there has been a success for reimbursement in Germany and elsewhere, Klees says private payers in the United States have not yet been systematically covers treatments with focused ultrasound of the uterus.
In fact, some have adopted a ‘negative’ policies that actively seek to deny coverage.